Condition
Advanced Non-small Cell Lung Cancer
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 48 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
48 shownA Study of [68Ga]Ga-DWJ155 in Adult Patients With Solid TumorsNCT07801508 · 2026-09-08
RECRUITINGEvaluation of JSKN016 Combination Therapy in Subjects With NSCLCNCT06868732 · 2025-04-02
RECRUITINGAlmonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung CanceNCT06043973 · 2023-09-01
RECRUITINGA Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung CancerNCT05482568 · 2022-09-15
RECRUITINGFirst in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)NCT05099172 · 2021-10-25
RECRUITINGPharmacokinetic Study of HS-10241 Tablets in Subjects with Hepatic Impairment and Normal Hepatic FunctionNCT06823245 · 2025-02-28
NOT_YET_RECRUITINGEvaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance： a Phase II Clinical StudyNCT06775483 · 2025-01-17
NOT_YET_RECRUITINGClinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLCNCT06434103 · 2024-10-10
WITHDRAWNClinical Trial of TQB2928 in Combination With a Third-Generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Patients With Advanced Non-Small Cell Lung CancersNCT06585059 · 2024-09-01
NOT_YET_RECRUITINGA Study to Learn About How BAY2927088 Affects the Level of Midazolam in the Blood When Both Drugs Are Taken Together in Healthy ParticipantsNCT06360211 · 2024-04-17
COMPLETEDA Study to Learn About How Itraconazole and Carbamazepine Affect the Level of BAY2927088 in the Blood When These Drugs Are Taken Together by Healthy ParticipantsNCT06348888 · 2024-04-10
COMPLETEDA Study to Learn About How Food and Esomeprazole Affect the Level of BAY2927088 in the Blood When Taken Together in Healthy ParticipantsNCT06378658 · 2024-03-29
COMPLETEDA Study to Learn About How BAY2927088 Affects the Level of Dabigatran or Rosuvastatin in the Blood When These Drugs Are Taken Together in Healthy ParticipantsNCT06329895 · 2024-03-25
COMPLETEDEvaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) ParticipantsNCT06269133 · 2024-02-21
ACTIVE_NOT_RECRUITINGA Study to Learn How BAY2927088 is Taken up and Handled by the Body in Healthy Male ParticipantsNCT06221475 · 2024-01-25
COMPLETEDObservational Cohort Study of Advanced Non-small Cell Lung Cancer (CAPTRA-LUNG)NCT03334864 · 2022-11-03
UNKNOWNVIC-1911 Combined With Osimertinib for EGFR -Mutant Non-small Cell Lung CancerNCT05489731 · 2022-09-21
UNKNOWNPhase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung CancerNCT05416775 · 2022-08-15
UNKNOWNStudy of KN046 in Subjects With Advanced Non-Small Cell Lung CancerNCT05420220 · 2022-07-26
COMPLETEDA Phase II Trial of AK104 in Advanced Non-Small Cell Lung CancerNCT05215067 · 2022-05-13
COMPLETEDKN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 AgentNCT05001724 · 2021-10-28
TERMINATEDAdoptive TKC Transfer Combined With Chemotherapy for Advanced Non-small Cell Lung Cancer (NSCLC)NCT04990063 · 2021-08-08
UNKNOWNA Study of SHR-A1811 in Subjects With Advanced Non-small Cell Lung CancerNCT04818333 · 2021-04-23
UNKNOWNThe Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung CancerNCT04699123 · 2021-02-04
ACTIVE_NOT_RECRUITINGEvaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung CancerNCT04263051 · 2020-09-09
COMPLETEDBronchoscopic Cryo-Immunotherapy of Lung CancerNCT04049474 · 2020-02-15
COMPLETEDImpact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in OncologyNCT03948724 · 2019-12-11
COMPLETEDEfficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Early Stereotactic Body Radiation Therapy to the Primary Tumor in Advanced Non-small Cell Lung CancerNCT03727867 · 2019-06-01
UNKNOWNClinical Study of Utidelone Injection in Patients With Advanced Non-small Cell Lung Cancer（NSCLC）NCT03693547 · 2019-04-22
COMPLETEDAbivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR MutationNCT03856697 · 2019-03-01
UNKNOWNRO5126766 for Patients With Advanced KRAS-Mutant Lung CancerNCT03681483 · 2018-10-31
COMPLETEDAST-VAC2 Vaccine in Patients With Non-small Cell Lung CancerNCT03371485 · 2018-05-29
COMPLETEDEvaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC)NCT03014648 · 2017-07-18
COMPLETEDBinimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC.NCT02964689 · 2017-04-12
COMPLETEDVigil™ + Nivolumab in Advanced Non-Small Cell Lung CancerNCT02639234 · 2016-03-01
WITHDRAWNONO-4538 Study in Patients With Advanced Non-Small Cell Lung CancerNCT02582125 · 2016-01-27
COMPLETEDThe Safety and Efficacy of Pemetrexed Rechallenge With BevacizumabNCT02200354 · 2014-07-01
TERMINATEDA Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid MalignanciesNCT02108964 · 2014-06-06
COMPLETEDA First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced CancerNCT02038699 · 2014-01-01
WITHDRAWNTumor Relapsed Study of Serum Trxr Activity in Advanced Non-small Cell Lung CancerNCT01980212 · 2013-05-01
COMPLETEDModulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase IINCT01649947 · 2011-12-23
COMPLETEDRecombinant Endostatin Combined With Vinorelbine and Cisplatin in Patients With Advanced Non-small Cell Lung CancerNCT03117335 · 2011-11-10
COMPLETEDImmunotherapy With Racotumomab Versus Support Treatment in Advanced Non-small Cell Lung Cancer PatientsNCT01240447 · 2009-09-01
COMPLETEDPhase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor TypesNCT00633789 · 2008-06-01
COMPLETEDPaclitaxel Plus Carboplatin With or Without Endostar in Patients With Advanced Non-small Cell Lung CancerNCT00708812 · 2007-07-01
COMPLETEDPhase II Study of Combination of Paclitaxel Poliglumex and Alimta for Advanced Non-small Cell Lung Cancer (NSCLC)NCT00487669 · 2006-10-01
COMPLETEDStudy of Rofecoxib and Prolonged Constant Infusion of Gemcitabine in the Polychemotherapy Treatment of Advanced NSCLCNCT00385606 · 2003-01-01
COMPLETEDExpanded Access to Provide Sevabertinib (BAY 2927088) for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 MutationNCT06761976
AVAILABLECommon interventions
BAY2927088DRUG4DocetaxelDRUG4CarboplatinDRUG2CisplatinDRUG2JSKN016DRUG2PembrolizumabDRUG2[14C]-BAY2927088 oral solutionDRUG1[14C]-BAY2927088 solution for infusionDRUG1[68Ga]Ga-DWJ155DIAGNOSTIC_TEST1Abivertinib Maleate CapsulesDRUG1Adebrelimab；platinum-based chemotherapyDRUG1Adoptive TKC transfer therapyBIOLOGICAL1AK104DRUG1almonertinibDRUG1AST-VAC2BIOLOGICAL1AtezolizumabDRUG1AxitinibCOMBINATION_PRODUCT1BAY2927088 coated tablet 10 mgDRUG1BAY2927088_formulation ADRUG1BAY2927088_formulation B_1DRUG1BAY2927088_formulation B_2DRUG1BAY2927088_formulation B_3DRUG1Best support treatmentOTHER1BevacizumabDRUG1BinimetinibDRUG1
Leading sponsors
Bayer7Jiangsu Alphamab Biopharmaceuticals Co., Ltd4Jiangsu HengRui Medicine Co., Ltd.2Novartis Pharmaceuticals2Suzhou Suncadia Biopharmaceuticals Co., Ltd.2Akeso1Beijing Biostar Pharmaceuticals Co., Ltd.1Bristol-Myers Squibb1Cancer Research UK1Centre Hospitalier Universitaire de Besancon1Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.1Dartmouth-Hitchcock Medical Center1Gradalis, Inc.1Haihua Yang1Hangzhou ACEA Pharmaceutical Research Co., Ltd.1
Trial status mix
COMPLETED25
UNKNOWN7
RECRUITING5
NOT_YET_RECRUITING3
WITHDRAWN3
ACTIVE_NOT_RECRUITING2
TERMINATED2
AVAILABLE1
Phase mix
PHASE224
PHASE121
PHASE36
EARLY_PHASE11
NA1
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.